Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials.

Eur J Med Res · 2023 · PMC10463988 · PMID 37635242

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

marginally significantp = 0.06so close (0.05 < p ≤ 0.1)

For patients with brain metastasis at baseline, the combination therapy achieved a significant better PFS than the monotherapy (HR = 0.60, 95% CI 0.39–0.90; p = 0.01), and a better OS with the difference marginally significant (HR = 0.69, 95% CI 0.46–1.02; p = 0.06).

also in 26,082 other papers

a positive trendp = 0.06so close (0.05 < p ≤ 0.1)

The subgroup analysis suggested that the combination therapy not only provided significant improvement in PFS (HR = 0.60, 95% CI 0.39–0.90; p = 0.01), but also had a positive trend to prolong OS (HR = 0.69, 95% CI: 0.46–1.02; p = 0.06) in patients with brain metastasis (Fig. 4 A, B).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.